Sleep apnoea is a common but often underdiagnosed condition where breathing repeatedly stops and starts during sleep, disrupting deep rest and leading to chronic fragmentation of sleep cycles. Research suggests that it affects around 1.5 million people in the UK alone, with men being nearly twice as likely to be diagnosed as women. Untreated, it can severely impair cognitive performance, increase the risk of depression, and elevate long-term cardiovascular risks. The condition is particularly insidious because its symptoms—such as daytime fatigue, memory lapses, and mood swings—are frequently misattributed to stress or ageing.
One of the most critical consequences of sleep apnoea is its detrimental effect on executive function, including memory, attention, and problem-solving. A landmark study published in web page found that individuals with moderate to severe obstructive sleep apnoea (OSA) scored significantly lower on cognitive tests compared to those without the condition, with a 30% reduction in processing speed and a 25% decline in working memory. These deficits are not merely temporary; they persist even after patients achieve normal sleep patterns through treatment, underscoring the need for early intervention. Neuroscientists argue that the brain’s compensatory mechanisms, which attempt to mitigate sleep deprivation, can become overworked, leading to lasting neurological damage.
The mental health implications of sleep apnoea extend beyond cognitive decline, with depression and anxiety disorders frequently co-occurring. A 2020 meta-analysis in the The Lancet Psychiatry revealed that patients with OSA were nearly twice as likely to develop major depressive disorder compared to the general population. The link appears bidirectional: depression can exacerbate sleep apnoea symptoms, creating a vicious cycle that further deteriorates mental health. Sleep specialists emphasise that addressing OSA through continuous positive airway pressure (CPAP) therapy can improve mood and reduce depressive symptoms, though adherence remains a significant challenge for many.
Cardiovascular risks are another major concern, with OSA independently increasing the likelihood of hypertension, arrhythmias, and stroke. The UK’s National Institute for Health and Care Excellence (NICE) recommends that all patients with hypertension undergo a sleep study if symptoms of apnoea are suspected, given that untreated OSA is a leading modifiable risk factor for heart disease. The economic burden is substantial: in England alone, the annual cost of OSA-related healthcare is estimated at £1.3 billion, covering both direct medical expenses and lost productivity. This highlights the importance of public health campaigns to raise awareness and encourage early diagnosis.
Diagnosis remains one of the biggest barriers to effective treatment. Many cases go undetected because symptoms are subtle, and sleep studies—traditionally the gold standard—are often underused. Home sleep testing, which allows patients to monitor their breathing at home, has become a more accessible option, though it is still underutilised in primary care settings. The NHS’s recent expansion of sleep clinics in response to the pandemic has improved access, but disparities persist in rural areas where specialist services are scarce.
While treatment options like CPAP, oral appliances, and weight management strategies are well-established, lifestyle changes play a crucial role in long-term management. Regular physical activity, avoiding alcohol and sedatives before bed, and maintaining a consistent sleep schedule can all reduce apnoea severity. For those who struggle with CPAP, alternative therapies such as positional therapy—where patients wear devices to prevent lying on their back—have shown promising results in reducing symptoms.
The future of sleep apnoea research lies in personalised medicine, where genetic and biomarker data could help tailor treatments more effectively. Early studies suggest that certain genetic variants may influence susceptibility to OSA, offering potential targets for preventive interventions. Until then, public education remains vital: understanding the signs—such as loud snoring, gasping during sleep, and persistent fatigue—can prompt timely action and save lives.
- Approximately 1.5 million people in the UK have untreated sleep apnoea, with men at higher risk.
- Untreated OSA is linked to a 30% reduction in processing speed and a 25% decline in working memory.
- Patients with OSA are nearly twice as likely to develop major depressive disorder.
- The annual healthcare cost of OSA in England is estimated at £1.3 billion.
- Home sleep testing has reduced reliance on expensive in-lab studies but remains underutilised.